# Airsculpt Technologies, Inc.: overview AIRS · Nasdaq · CIK 1870940 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/airs.md) · [Financials](/companies/airs/financials.md) · [Filings](/companies/airs/filings.md) · [Insiders](/companies/airs/insiders.md) Latest reported revenue: [$42.9m](/filings/0001870940-26-000038.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001870940-26-000038). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [42.5](/filings/0001870940-25-000040.md) | [39.2 d](/filings/0001870940-26-000021.md) | [39.4](/filings/0001870940-26-000028.md) | [44.0](/filings/0001870940-26-000038.md) | [35.0](/filings/0001870940-25-000040.md) | [33.4 d](/filings/0001870940-26-000021.md) | [39.4](/filings/0001870940-26-000028.md) | [42.9](/filings/0001870940-26-000038.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(8.7%)](/filings/0001870940-25-000040.md) | [(9.9%) d](/filings/0001870940-26-000021.md) | [(4.0%)](/filings/0001870940-26-000028.md) | [1.8%](/filings/0001870940-26-000038.md) | [(27.9%)](/filings/0001870940-25-000040.md) | [(3.0%) d](/filings/0001870940-26-000021.md) | [(4.6%)](/filings/0001870940-26-000028.md) | [(0.1%)](/filings/0001870940-26-000038.md) | | Net margin | % | [(14.2%)](/filings/0001870940-25-000040.md) | [(12.3%) d](/filings/0001870940-26-000021.md) | [(7.2%)](/filings/0001870940-26-000038.md) | [(1.3%)](/filings/0001870940-26-000038.md) | [(27.2%)](/filings/0001870940-25-000040.md) | [3.8% d](/filings/0001870940-26-000021.md) | [(6.1%)](/filings/0001870940-26-000038.md) | [(2.6%)](/filings/0001870940-26-000038.md) | | Diluted EPS | $ per share | [(0.10)](/filings/0001870940-25-000040.md) | not reported | [(0.05)](/filings/0001870940-26-000028.md) | [(0.01)](/filings/0001870940-26-000038.md) | [(0.15)](/filings/0001870940-25-000040.md) | not reported | [(0.03)](/filings/0001870940-26-000028.md) | [(0.02)](/filings/0001870940-26-000038.md) | | Free cash flow | $m | [(3.1) d](/filings/0001870940-25-000040.md) | [(0.8) d](/filings/0001870940-26-000021.md) | [(1.0)](/filings/0001870940-26-000028.md) | [4.7 d](/filings/0001870940-26-000038.md) | [(0.4) d](/filings/0001870940-25-000040.md) | [(2.6) d](/filings/0001870940-26-000021.md) | [5.2](/filings/0001870940-26-000028.md) | [(1.5) d](/filings/0001870940-26-000038.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [133](/filings/0001870940-24-000005.md) | [169](/filings/0001870940-25-000008.md) | [196](/filings/0001870940-26-000021.md) | [180](/filings/0001870940-26-000021.md) | [152](/filings/0001870940-26-000021.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [11.8%](/filings/0001870940-24-000005.md) | [(2.7%)](/filings/0001870940-25-000008.md) | [5.0%](/filings/0001870940-26-000021.md) | [(0.9%)](/filings/0001870940-26-000021.md) | [(7.6%)](/filings/0001870940-26-000021.md) | | Net margin | % | [7.9%](/filings/0001870940-24-000005.md) | [(8.7%)](/filings/0001870940-25-000008.md) | [(2.2%)](/filings/0001870940-26-000021.md) | [(4.4%)](/filings/0001870940-26-000021.md) | [(7.7%)](/filings/0001870940-26-000021.md) | | Diluted EPS | $ per share | [(0.01)](/filings/0001870940-24-000005.md) | [(0.26)](/filings/0001870940-25-000008.md) | [(0.08)](/filings/0001870940-26-000021.md) | [(0.14)](/filings/0001870940-26-000021.md) | [(0.19)](/filings/0001870940-26-000021.md) | | Free cash flow | $m | [19.5](/filings/0001870940-24-000005.md) | [11.5](/filings/0001870940-25-000008.md) | [14.0](/filings/0001870940-26-000021.md) | [(2.7)](/filings/0001870940-26-000021.md) | [0.7](/filings/0001870940-26-000021.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/airs/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Vesey Street Capital Partners, L.L.C.](/funds/1910342.md) | 2026-06-30 | $136.5m | 30,324,180 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $5.8m | 1,278,871 | | Added +474,792 | | [WEXFORD CAPITAL LP](/funds/1048462.md) | 2026-06-30 | $3.8m | 841,734 | | Added +171,217 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $3.6m | 792,183 | | Added +169,891 | | [FourWorld Capital Management LLC](/funds/1770525.md) | 2026-06-30 | $3.4m | 750,000 | | Reduced −237,757 | | [FLPUTNAM INVESTMENT MANAGEMENT CO](/funds/1140334.md) | 2026-06-30 | $3.1m | 691,989 | | New +691,989 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $2.1m | 470,723 | | Added +161,394 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $2.0m | 451,224 | | Added +82,768 | | [CenterBook Partners LP](/funds/1872738.md) | 2026-06-30 | $1.8m | 391,812 | | New +391,812 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $1.7m | 373,324 | | New +373,324 | ## Recent filings [All 248 filings](/companies/airs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-12 | 17:42 ET | [8-K](/filings/0001870940-26-000041.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001870940-26-000041 | | 2026-08-10 | 09:37 ET | [10-Q](/filings/0001870940-26-000038.md) | Quarterly report, period 2026-06-30 | 0001870940-26-000038 | | 2026-08-10 | 06:09 ET | [8-K](/filings/0001870940-26-000036.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001870940-26-000036 | | 2026-05-14 | 18:24 ET | [8-K](/filings/0001870940-26-000031.md) | 5.07 Shareholder vote results | 0001870940-26-000031 | | 2026-05-08 | 16:21 ET | [10-Q](/filings/0001870940-26-000028.md) | Quarterly report, period 2026-03-31 | 0001870940-26-000028 | | 2026-05-08 | 06:35 ET | [8-K](/filings/0001870940-26-000026.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001870940-26-000026 | | 2026-04-15 | 16:05 ET | [DEF 14A](/filings/0001104659-26-043792.md) | Proxy statement, period 2026-05-12 | 0001104659-26-043792 | | 2026-04-06 | 06:32 ET | [8-K/A](/filings/0001870940-26-000022.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001870940-26-000022 | | 2026-04-06 | 06:32 ET | [10-K/A](/filings/0001870940-26-000021.md) | Annual report, amended, period 2025-12-31 | 0001870940-26-000021 | | 2026-04-02 | 06:31 ET | [8-K](/filings/0001870940-26-000016.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001870940-26-000016 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001870940-26-000011.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5e65cf71-8e6a-43ae-832b-9459b5451e10) ## About the filer - CIK: 1870940 - Tickers: AIRS - Exchange: Nasdaq - SIC code: 8011 Services-Offices & Clinics of Doctors of Medicine - State of incorporation: not reported - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.